News

Regeneron's 23andMe Steal - Smart Genetics Play That Won't Cure Near-Term Growth Pains
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.
Regeneron agrees to buy bankrupt 23andMe, promises ethical use of customers' DNA data
Regeneron Pharmaceuticals said on Monday it will buy genetic testing firm 23andMe Holding for $256 million through a ...
Lohud.com, Westchester County on MSN1d
Regeneron to acquire 23andMe DNA testing firm. How that could impact your genetic data
Regeneron announced a plan to acquire genetic testing firm 23andMe through bankruptcy court, including access to personal ...
23andMe sells its most valuable asset to biotech company Regeneron, which promises to keep your DNA private
Regeneron said it will continue uninterrupted service of 23andMe’s consumer genome services after its purchase closes as ...
Daily Voice on MSN23h
Westchester-Based Regeneron Buying Bankrupt 23andMe For $256M, Pledges To Protect DNA Data
Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...
23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.
Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles ...
Stocktwits on MSN1d
Regeneron To Buy Assets Of 23andMe For $256M: Retail Says ‘Fantastic’ For Future R&D Efforts
Drugmaker Regeneron Pharmaceuticals, Inc. (REGN) said on Monday that it will acquire the assets of bankrupt biotechnology ...